N-[2-methoxy-5-(trifluoromethyl)phenyl]({3-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl}amino)carboxamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[2-methoxy-5-(trifluoromethyl)phenyl]({3-[2-(N-methylcarbamoyl)(4-pyridyloxy)]phenyl}amino)carboxamide
• 英文别名: N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea；N-(2-methoxy-5-(trifluoromethyl)phenyl)-N'-(3-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)phenyl)-urea；4-[3-[[2-methoxy-5-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
• 化学式: C₂₂H₁₉F₃N₄O₄
• 分子量: 460.412
• InChiKey: JQRCJEFLYSNDOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
  申请人：BAYER CORPORATION

  公开号：US20030207872A1

  公开（公告）日：2003-11-06

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
  申请人：BAYER CORPORATION

  公开号：US20030181442A1

  公开（公告）日：2003-09-25

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
  申请人：BAYER CORPORATION

  公开号：US20030144278A1

  公开（公告）日：2003-07-31

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
  申请人：——

  公开号：US20010011135A1

  公开（公告）日：2001-08-02

  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

  这项发明涉及使用一组芳基脲类化合物治疗raf介导的疾病，以及用于该疗法的药物组合物。
• ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
  申请人：Bayer Healthcare LLC

  公开号：US20160015697A1

  公开（公告）日：2016-01-21

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  这项发明涉及使用芳基脲类化合物治疗由异常血管生成或高渗透性过程特征的VEGF诱导信号转导通路介导的疾病的方法。